Accord Healthcare Inc. has won FDA approval for the generic version of methotrexate sodium, widening the competitive landscape for this widely prescribed oncology and rheumatoid arthritis medication. The authorization of this oral formulation is expected to exert downward pressure on prices amidst robust demand for affordable oral dosing options.